Date: 2013-03-05
Type of information: R&D agreement
Compound: Riboxxim®
Company: Riboxx Pharmaceuticals (Germany) China National Biotec Group Company Limited (CNBG - China)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism: The proprietary TLR3 agonist of Riboxx, Riboxxim®, is a class of synthetic, highly pure and precisely defined nucleic acids molecules manufactured by TENPORA®, a proprietary process of Riboxx. These molecules are capable of triggering innate immune responses through TLR-3 activation, enabling novel immunization approaches both in prophylactic vaccines (e.g. against infections) and in therapeutic vaccines (e.g. against cancer).
Disease: undisclosed
Details: Riboxx Pharmaceutical and China National Biotec Group Company Limited (CNBG) have initiated a research collaboration to evaluate Riboxxim®, a TLR3 agonist from Riboxx, with an antigen of CNBG against one of the world’s deadliest infectious diseases. During the term of the research collaboration, Riboxx will provide access to Riboxxim® to enable CNBG to perform an evaluation in conjunction with CNBG’s antigen against the disease target.
Financial terms:
Latest news:
